Literature DB >> 23295983

Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.

Kuang Youlin1, Zhang Li, Gou Xin, Xiao Mingchao, Liu Xiuheng, Weng Xiaodong.   

Abstract

Interactions between costimulatory molecules and their receptors are vital for Ag-presenting dendritic cells (DCs) to initiate T cells activation, expansion and their antitumor immune responses. Augmentation of costimulatory signal due to the interaction of DCs and T cells may amplify, sustain and drive diversity of cytotoxic T lymphocytes (CTLs) and consequently enhance the antitumor response. 4-1BBL/4-1BB is such a pair of costimulatory ligand and receptor, playing an important role in the co-stimulation of CTLs. Previously, we demonstrated that DCs transduced with recombinant adenovirus encoding truncated PSMA (tPSMA) and m4-1BBL could induce prostate cancer regression in mouse models. In the present study, we further explored the adjuvant role of 4-1BBL in modulating CTLs activation induced by tPSMA gene-pulsed DCs. The apoptosis and cytotoxicity against tPSMA expressing RM-1 cells of CTLs were determined. Results showed that tPSMA gene-pulsed DCs effectively induced T lymphocyte activation and cytotoxicity, which was enhanced by upregulated expression of 4-1BBL, displaying better cell viability, lower CTLs apoptosis, higher expression anti-apoptotic protein of Bcl-xL and phosphorylation of P38, enhanced NF-κB activation, as well as more IFN-γ production. These results demonstrated that 4-1BBL may play a significant role in the co-stimulation pathway for Ag-presenting DCs-mediated CTLs activity, which might be a beneficial adjuvant factor for DCs-based cancer immunotherapy.

Entities:  

Keywords:  4-1BBL; costimulatory molecule; cytotoxic T lymphocytes; dendritic cells; prostate cancer

Mesh:

Substances:

Year:  2013        PMID: 23295983      PMCID: PMC3903894          DOI: 10.4161/hv.23116

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  38 in total

1.  Adoptive T-cell therapy for malignant disorders.

Authors:  Daniel J Powell; Bruce L Levine
Journal:  Haematologica       Date:  2008-10       Impact factor: 9.941

2.  Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.

Authors:  Youlin Kuang; Xiaodong Weng; Xiuheng Liu; Hengchen Zhu; Zhiyuan Chen; Botao Jiang; Hui Chen
Journal:  Cancer Lett       Date:  2010-02-09       Impact factor: 8.679

Review 3.  Immunotherapy for the treatment of prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Philip W Kantoff
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

4.  Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.

Authors:  Laura Ridolfi; Massimiliano Petrini; Laura Fiammenghi; Anna Maria Granato; Valentina Ancarani; Elena Pancisi; Claudia Brolli; Mirna Selva; Emanuela Scarpi; Linda Valmorri; Stefania Vittoria Luisa Nicoletti; Massimo Guidoboni; Angela Riccobon; Ruggero Ridolfi
Journal:  Melanoma Res       Date:  2011-12       Impact factor: 3.599

5.  Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.

Authors:  D Eaton; D E Gilham; A O'Neill; R E Hawkins
Journal:  Gene Ther       Date:  2002-04       Impact factor: 5.250

6.  Selective induction of high avidity CTL by altering the balance of signals from APC.

Authors:  SangKon Oh; James W Hodge; Jeffrey D Ahlers; Donald S Burke; Jeffrey Schlom; Jay A Berzofsky
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

7.  Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.

Authors:  T Yoshikawa; T Niwa; H Mizuguchi; N Okada; S Nakagawa
Journal:  Gene Ther       Date:  2008-05-15       Impact factor: 5.250

8.  4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells.

Authors:  Diego Laderach; Mojgan Movassagh; Anthony Johnson; Robert S Mittler; Anne Galy
Journal:  Int Immunol       Date:  2002-10       Impact factor: 4.823

9.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 10.  The use of dendritic cells in cancer immunotherapy.

Authors:  Alessio Nencioni; Frank Grünebach; Susanne M Schmidt; Martin R Müller; Davide Boy; Franco Patrone; Alberto Ballestrero; Peter Brossart
Journal:  Crit Rev Oncol Hematol       Date:  2007-12-04       Impact factor: 6.312

View more
  4 in total

Review 1.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

2.  Stimulation of murine cell-mediated immunity by dietary administration of a cell preparation of Enterococcus faecalis strain KH-2 and its possible activity against tumour development in mice.

Authors:  Takamitsu Tsukahara; Shin-Ichi Nakamura; Gustavo A Romero-Pèrez; Makoto Ohwaki; Takaharu Yanagisawa; Tatsuhiko Kan
Journal:  Biosci Microbiota Food Health       Date:  2018-03-28

Review 3.  Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.

Authors:  Daniele E Mascarelli; Rhubia S M Rosa; Jessica M Toscaro; Isadora F Semionatto; Luciana P Ruas; Carolinne T Fogagnolo; Gabriel C Lima; Marcio C Bajgelman
Journal:  Front Cell Dev Biol       Date:  2021-06-30

4.  Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Authors:  Edwin Bremer
Journal:  ISRN Oncol       Date:  2013-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.